| Year |
Revenue |
EBITDA |
Margin |
Status |
| FY2020Yr ended Apr 2020 |
$18.3M |
$4.4M |
24% |
Pre-investment |
| FY2021Deal closed Mar 2021 |
$28.9M |
$7.7M |
27% |
Deal year |
| FY2022First full year |
$46.7M |
$12.0M |
26% |
Post-investment |
| FY2023 |
~$54.5M |
~$13.1M |
~24% |
Post-investment |
| FY2025 |
$75.1M |
N/A |
N/A |
Post-investment |
Sources: Companies House full accounts, LeMieux Ltd / Horse Health Wessex Ltd (04656887), FY2020 to FY2022 (all audited). FY2021 EBITDA from FY2022 strategic report comparative. FY2023 from trade press (company-cited figures); EBITDA estimated at stated margin. FY2025 from LDC press release, August 2025. Italicised figures are estimates. All figures in USD at $1.27/GBP.